| HOME >> BIOLOGY >> TECHNOLOGY |
----------------------------------------------------------
Pin Code 3238234 followed by the number sign
----------------------------------------------------------
Vasogen also announced today that its President and Chief Executive Officer, Chris Waddick, will present a Company overview at Bio InvestorForum 2007 on October 10, 2007, at 12:15 p.m. Pacific Time (3:15 p.m. ET) at the Palace Hotel, San Francisco. A live audio web cast and slide presentation of this event can be accessed through Vasogen's Website at: http://www.vasogen.com. An archived replay will be available following the presentation.
About Vasogen:
Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) technology, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and is preparing to advance VP025, the lead drug candidate from this new class, into phase II development.
Certain statements contained in this press release, the upcoming
conference call and webcasts, or elsewhere in our public documents
constitute "forward-looking statements" within the meaning of the United
States Private Securities Litigation Reform Act of 1995 and/or
"forward-looking information" under the Securities Act (Ontario). These
statements may include, without limitation, pl
'/>"/>
| SOURCE Vasogen Inc. Copyright©2007 PR Newswire. All rights reserved |